Skip to content
Head to head

Cytokinetics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: CYTK · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

CYTK -24.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
CYTKVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price50.78515.02
Change today-1.32%-1.08%
1-year return-20.0%+22.0%
Market cap$7.07B$130.58B
52-week range50.32 – 88.31412.27 – 568.67
Valuation
P/E (TTM)-8.4433.14
P/E percentile, own 5-yr range65th99th
P/B-22.026.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-6.5415.32
Net profit (TTM)$-911.04M$3.88B
Revenue (TTM)$113.29M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+2356.5%+11.8%
Gross margin--85.5%
Operating margin-625.2%33.1%
Net margin-686.6%30.7%
Free cash flow (TTM)$-588.58M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership118.2%96.8%
Insider activity (12mo)16 buy / 34 sell28 buy / 22 sell
Short interest (% of float)12.9%1.9%
Analyst consensus94% buy / 6% hold (16)95% buy / 5% hold (21)
Analyst price target$107 (+111%)$624 (+21%)
StockVane view
StockVane Quant RatingD (19)C (68)
Company
Employees6736,400
Founded19971989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.